144 related articles for article (PubMed ID: 20335370)
1. Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers.
Russo P; Mennini FS; Siviero PD; Rasi G
Ann Oncol; 2010 Oct; 21(10):2081-2087. PubMed ID: 20335370
[TBL] [Abstract][Full Text] [Related]
2. Disparity in the "time to patient access" to new anti-cancer drugs in Italian regions. Results of a survey conducted by the Italian Society of Medical Oncology (AIOM).
Gori S; Di Maio M; Pinto C; Alabiso O; Baldini E; Barbato E; Beretta GD; Bravi S; Caffo O; Canobbio L; Carrozza F; Cinieri S; Cruciani G; Dinota A; Gebbia V; Giustini L; Graiff C; Molino A; Muggiano A; Pandoli G; Puglisi F; Tagliaferri P; Tomao S; Venturini M;
Tumori; 2011; 97(4):442-8. PubMed ID: 21989431
[TBL] [Abstract][Full Text] [Related]
3. Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods.
Leyens L; Brand A
Public Health Genomics; 2016; 19(3):187-91. PubMed ID: 27238553
[TBL] [Abstract][Full Text] [Related]
4. Early access for innovative oncology medicines: a different story in each nation.
Cowling T; Nayakarathna R; Wills AL; Tankala D; Paul Roc N; Barakat S
J Med Econ; 2023; 26(1):944-953. PubMed ID: 37466223
[TBL] [Abstract][Full Text] [Related]
5. MONITORING REGISTRIES AT ITALIAN MEDICINES AGENCY: FOSTERING ACCESS, GUARANTEEING SUSTAINABILITY.
Montilla S; Xoxi E; Russo P; Cicchetti A; Pani L
Int J Technol Assess Health Care; 2015 Jan; 31(4):210-3. PubMed ID: 26646859
[TBL] [Abstract][Full Text] [Related]
6. Access in all areas? a round up of developments in market access and health technology assessment: part 4.
Beattie A; Treharne C; Ramagopalan SV
J Comp Eff Res; 2024 Jun; 13(6):e240060. PubMed ID: 38647164
[TBL] [Abstract][Full Text] [Related]
7. Time to Entry for New Cancer Medicines: From European Union-Wide Marketing Authorization to Patient Access in Belgium, Estonia, Scotland, and Sweden.
Ferrario A
Value Health; 2018 Jul; 21(7):809-821. PubMed ID: 30005753
[TBL] [Abstract][Full Text] [Related]
8. Market and patient access to new oncology products in Europe: a current, multidisciplinary perspective.
McCabe C; Bergmann L; Bosanquet N; Ellis M; Enzmann H; von Euler M; Jönsson B; Kallen KJ; Newling D; Nüssler V; Paschen B; de Wilde R; Wilking N; Teale C; Zwierzina H;
Ann Oncol; 2009 Mar; 20(3):403-12. PubMed ID: 18854550
[TBL] [Abstract][Full Text] [Related]
9. Optimizing patient referral and center capacity in the management of chronic hepatitis C: Lessons from the Italian experience.
Alberti A; Angarano G; Colombo M; Craxì A; Di Marco V; Di Perri G; Gaeta GB; Ippolito G; Mangia A; Pasqualetti P
Clin Res Hepatol Gastroenterol; 2019 Apr; 43(2):190-200. PubMed ID: 30377096
[TBL] [Abstract][Full Text] [Related]
10. [EMA approval procedures and assessment of innovation by AIFA: a cross sectional analysis.].
Lasala R
Recenti Prog Med; 2021 Apr; 112(4):273-284. PubMed ID: 33877088
[TBL] [Abstract][Full Text] [Related]
11. Differences in the availability of new anti-cancer drugs for Italian patients treated in different regions. Results of analysis conducted by the Italian Society Of Medical Oncology (AIOM).
Gori S; Di Maio M; Pinto C; Alabiso O; Baldini E; Beretta GD; Caffo O; Caroti C; Crinò L; De Laurentiis M; Dinota A; Di Vito F; Gebbia V; Giustini L; Graiff C; Guida M; Lelli G; Lombardo M; Muggiano A; Puglisi F; Romito S; Salvagno L; Tagliaferri P; Terzoli E; Venturini M;
Tumori; 2010; 96(6):1010-5. PubMed ID: 21388067
[TBL] [Abstract][Full Text] [Related]
12. [Counterfeit Medicines in Internet and the Fakeshare European Project: Experiences and Activities in Spain].
Catalán-Matamoros D; González-Ochando N; Pecharroman-Arribas H; Fernández-Muelas A; Bentolila-Benchimol SS; IbarraLorente M
Rev Esp Salud Publica; 2016 Aug; 90():e1-e14. PubMed ID: 27529446
[TBL] [Abstract][Full Text] [Related]
13. Comparing patient access to pharmaceuticals in the UK and US.
Cohen J; Cairns C; Paquette C; Faden L
Appl Health Econ Health Policy; 2006; 5(3):177-87. PubMed ID: 17132032
[TBL] [Abstract][Full Text] [Related]
14. Key drivers of innovativeness appraisal for medicines: the Italian experience after the adoption of the new ranking system.
Galeone C; Bruzzi P; Jommi C
BMJ Open; 2021 Jan; 11(1):e041259. PubMed ID: 33441356
[TBL] [Abstract][Full Text] [Related]
15. Time to access to novel anticancer drugs and the correlation with ESMO-Magnitude of Clinical Benefit Scale in Slovenia.
Janzic U; Knez L; Janzic A; Cufer T
Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):717-723. PubMed ID: 31826655
[No Abstract] [Full Text] [Related]
16. Skip pattern approach toward the early access of innovative anticancer drugs.
Apolone G; Ardizzoni A; Biondi A; Bortolami A; Cardone C; Ciniselli CM; Conte P; Crippa C; de Braud F; Duca M; Gori S; Gritti G; Inno A; Luksch R; Lussana F; Maio M; Pasello G; Perrone F; Rambaldi A; Rossi G; Signorelli D; Soverini G; Valente M; Verderio P; Buzzetti G
ESMO Open; 2021 Aug; 6(4):100227. PubMed ID: 34352703
[TBL] [Abstract][Full Text] [Related]
17. [Early achievements of the Danish pharmaceutical industry--8. Lundbeck].
Grevsen JV; Kirkegaard H; Kruse E; Kruse PR
Theriaca; 2016; (43):9-61. PubMed ID: 27491172
[TBL] [Abstract][Full Text] [Related]
18. Value assessment of medicinal products by the Italian Medicines Agency (AIFA) and French National Authority for Health (HAS): Similarities and discrepancies.
Xoxi E; Di Bidino R; Leone S; Aiello A; Prada M
Front Med Technol; 2022; 4():917151. PubMed ID: 36134249
[TBL] [Abstract][Full Text] [Related]
19. Market uptake of biologic and small-molecule--targeted oncology drugs in Europe.
Obradovic M; Mrhar A; Kos M
Clin Ther; 2009 Dec; 31(12):2940-52. PubMed ID: 20110034
[TBL] [Abstract][Full Text] [Related]
20. New requirements for phase I trials: a challenge for Italian clinical research.
Marchesi E; Monti M; Nanni O; Bassi L; Piccinni-Leopardi M; Cagnazzo C
Tumori; 2018; 104(1):15-21. PubMed ID: 28799641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
